A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems

British Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2010, Pages 67-73

  Qian, Yifeng ^a   Ye, Xiaofei ^a   Du, Wenmin ^b   Ren, Jingtian ^c   Sun, Yalin ^a   Wang, Hainan ^a,d   Luo, Baozhang ^a   Gao, Qingbin ^a   Wu, Meijing ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Adverse Drug Reaction Monitoring Centre of Shanghai   (China)

^c National Center for ADR Monitoring   (China)

^d CENTER FOR DRUG EVALUATION   (China)

Author keywords

Adverse drug reaction; Drug drug interactions; Signal detection

Indexed keywords

ALPHA2A INTERFERON; AMANTADINE; AZITHROMYCIN; AZLOCILLIN; BENSERAZIDE PLUS LEVODOPA; CAPECITABINE; CEFUROXIME; CHLORPROMAZINE; CLINDAMYCIN; CYCLOSPORIN A; ERLOTINIB; FLEROXACIN; GEMCITABINE; GLICLAZIDE; LEVOFLOXACIN; METFORMIN; MEZLOCILLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; PENICILLIN G SODIUM; PIPERACILLIN; PREDNISONE; RIBAVIRIN; RISPERIDONE; SODIUM CHLORIDE; TRIHEXYPHENIDYL;

ANEMIA; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; COMPUTER SYSTEM; CONSTIPATION; DIARRHEA; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPOGLYCEMIA; INFORMATION PROCESSING; LEUKOPENIA; LUNG FUNCTION; NEUROSIS; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL DETECTION; SLEEP DISORDER; SWELLING; THROMBOCYTOPENIA; THYROID DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATABASES, FACTUAL; DRUG INTERACTIONS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MODELS, STATISTICAL;

EID: 72949106908     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03557.x     Document Type: Article

References (27)

1. Pirmohamed M, Orme M. Drug interactions of clinical importance. In : Davies's Textbook of Adverse Drug Reactions, 5th edn, eds Davies D, Ferner R, de Glanville H. London : Chapman & Hall Medical, 1998 888 912.
2. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. J Drug Saf 2003 26 : 159 186.
3. Alsheikh-Ali AA, Abourjaily HM, Karas RH. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol 2002 89 : 1308 1310.
4. Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol 1999 47 : 689 693.
5. Van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000 56 : 733 738.
6. DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. Proc KDD 2001; New York: ACM, 67-76.
7. Wu X, Barbarā D, Ye Y. Screening and interpreting multi-item associations based on log-linear modeling. Proc KDD 2003; New York: ACM, 276-85.
8. Almenoff JS, Dumouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interaction in the post-marketing setting. Pharmacoepidemiol Drug Saf 2003 12 : 517 521.
9. Norén GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex association and improved accuracy for rare events. Stat Med 2006 25 : 3740 3757.
10. Norén GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med 2008 27 : 6271 6272.
11. Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 2007 64 : 489 495.
12. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005 4 : 929 948.
13. National Adverse Drug Reaction Monitoring Center. WHO Adverse Reaction Terminology. Peking : China Medicine and Technology Press, 2003.
14. Committee of Chinese Pharmacopoeia. Chinese Pharmacopoeia. Peking : Chemical Industry Press, 2005.
15. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007 16 : 359 365.
16. Du W, Levine M, Wang L, Zhang Y, Yi C, Wang H, Wang X, Xie H, Xu J, Jin H, Wang T, Huang G, Wu Y. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai. Can J Clin Pharmacol 2007 14 : 40 4.
17. Ye X, Fu Z, Wang H, Du W, Wang R, Sun Y, Gao Q, He J. A computerized system for signal detection in spontaneous reporting system of Shanghai, China. Pharmacoepidemiol Drug Saf 2009 18 : 154 158.
18. Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002 25 : 453 458.
19. Skrondal A. Interaction as departure from additivity in case-control studies: a cautionary note. Am J Epidemiol 2003 158 : 251 258.
20. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980 112 : 467 470.
21. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992 3 : 452 456.
22. Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Eqberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting system for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002 11 : 3 10.
23. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO database. Drug Saf 2000 23 : 533 542.
24. Li C, Xia J, Deng J, Jiang J. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China. Pharmacoepidemiol Drug Saf 2008 17 : 593 600.
25. Lin F, Wang H. Concomitant nodular goiter during IFN and ribavirin treatment of HCV: a case report. Clin J Hepatol 2006 14 : 163 166.
26. Zhang J, Miao J, Zhao F, Chen S, Guo X. Analysis of effects of the combination of capecitabine and oxaliplatin as first-line chemotherapy on metastatic colorectal cancer. Mod Med J 2008 36 : 37 9.
27. Liang K, Li Y. Clinical observation of capecitabine combining oxaliplatin in the treatment of advanced colorectal carcinoma. Mod Oncol 2008 16 : 1365 1366.